NMRA Projected Dividend Yield
Neumora Therapeutics Inc ( NASDAQ : NMRA )Neumora Therapeutics is a clinical-stage biopharmaceutical company. Co. has scaled its therapeutic pipeline, which consists of seven clinical and preclinical neuroscience programs that target mechanisms of action for a range of neuropsychiatric disorders and neurodegenerative diseases. Co.'s primary product candidate, navacaprant (NMRA-140), is a once-daily oral kappa opioid receptor antagonist that is being developed for the treatment of major depressive disorder (MDD). Co. is initiating a Phase 3 program for navacaprant monotherapy in patients with moderate to severe MDD. 20 YEAR PERFORMANCE RESULTS |
NMRA Dividend History Detail NMRA Dividend News NMRA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |